Document is current
Any future updates will be listed below
-
Authors
Alshannaq, Hamza
Simmons, David
Matuoka, Jessica Y.
Pollock, Richard F.
Tucker, Matthew
Ahmed, Moin U.
Norman, Greg J.
-
Funding
Funding for this research was provided by:
Dexcom
- License Information
-
More Information
Article History
Received: 25 July 2025
Accepted: 5 November 2025
First Online: 5 December 2025
Declarations
:
: Jessica Matuoka and Greg Norman are employees of Dexcom and hold stock in Dexcom. Hamza Alshannaq is an employee of Neurocrine Biosciences and holds stock in Dexcom. Moin Uddin Ahmed declares no conflicts of interest. David Simmons is a Distinguished Professor at the Western Sydney University School of Medicine, Deputy Head of Department at the Macarthur Diabetes Endocrinology and Metabolism Services (MDEMS), and Chief Medical Officer of Diabetes Australia. David Simmons reports receipt of education grants from Abbott, Ascensia, and Boehringer Ingelheim; devices for research and clinical service development from Dexcom and Abbott; speaker fees from Novo Nordisk and Sanofi; and research support from Hitachi. Richard Pollock and Matthew Tucker are full-time employees of Covalence Research Ltd, which received consultancy fees from Dexcom to prepare the manuscript.
: As an economic modelling analysis based on published literature, the present study did not enroll human participants or make use of human biological samples or individually identifiable data, and ethics approval was therefore not required.
